Immunology and Immunotherapy 101 for the Non-Immunologist


Anupam Desai, MD
Beth Israel Deaconess Medical Center

I have no relevant conflicts of interest to disclose.


I will not be discussing non-FDA approved treatments.

Immunology Basics

Immune cells are derived from stem cells in the bone marrow



Myeloid cells





- Derived from a common progenitor
- Comprises most of the cells of the innate immune system
- Functional maturation may happen in tissue in response to danger signals





Granulocytes

Short-lived cells that possess granules containing degradative enzymes and anti-microbial substances










Neutrophils, eosinophils and basophils are sometimes referred to as polymorphonuclear leukoyctes (PMNs)




Phagocytes

Neutrophils, macrophages and dendritic cells



Reside in tissues




Main role is not clearance of pathogen but rather immune cell activation; patrolling population in lymphoid tissues as well as non-lymphoid tissues

Dendritic cells and macrophages are two types of professional antigen presenting cells (APCs)



Lymphocytes



B cells

 Produce antibodies (Ab) that bind proteins

T cells

 Various regulatory and cytotoxic functions

Natural Killer (NK) cells

- Kill tumor and virus-infected cells
- Kill antibody-coated cells
- Play dominant role in mediating ADCC in vivo

Adaptive


(recognize very specific antigens)

Innate

(recognize general features)




Lymphoid organs






Infectious agents first activate innate immune cells resulting in an inflammatory response



Cytokines are proteins that immune cells use to communicate/regulate other immune cells, not all cytokines are inflammatory

Chemokines are a group of cytokines that attract other immune cells

Innate responses are initiated upon recognition of "danger signals" by pattern recognition receptors (PRRs)



"Danger signals"

- Pathogen-associated molecular patterns (PAMPs)
 - Bacteria proteins
 - viral DNA/RNA
- Damage-associated molecular patterns (DAMPs)
 - Products of dying cells

Types of PRRs


- Toll-like receptors (TLR)
- C-type lectin receptors
- NOD-like receptors (NLRs)
- RIG-I-like receptors

Receptors can be on the cell surface or intracellular (NLRs)



Antigen processing and presentation

Professional APCs present Ag to naïve T cells and induce activation



Immature DCs very efficient at Ag processing (in tissues)


Mature DCs very

→ efficient at Ag presentation

(in LNs)



MHC Class I presents peptide antigens to CD8 T cells




Major Histocompatibility Complex (MHC) Class I

- Expressed by all nucleated cells
- Presents peptides derived from endogenous proteins
- MHC Class I proteins are also recognized by NK cells



MHC Class II presents antigens to CD4 T cells




Major Histocompatibility Complex (MHC) Class II

- Typically expressed by professional APCs
- Presents peptides derived from exogenous proteins




DCs are important for initiating adaptive immune responses





Adaptive immune responses




Antigen receptors

Antibody (Ab)

Schematic structure of an antibody molecule Variable region (antigen-binding site) Constant region (effector function) Cell surface and secreted


T cell receptor (TCR)






Antigen recognition by antibodies

Ab recognizes portions of proteins in native structures, not processed proteins (may not be continuous portion of protein)






T cell receptors (TCRs) recognize processed proteins presented by MHC



MHC = Major Histocompatibility Complex



Generating lymphocytes that each have a unique specificity



Generation of vast pool of cells

 Immature cells (non-functional)

Elimination of cells that can recognize self Ags


 One barrier to inducing responses against tumor cells

Mechanism of central tolerance

 Circulating mature naïve cells



Lymphocyte activation



Cells that recognize specific Ag are very rare

Results in:

- Expansion
- Acquisition of effector functions

What happens to T cells and B cells after immune response?

Differentiate into long-lived memory lymphocytes



Lymphocyte activation

Antigen receptor binding and co-stimulation of T cell by dendritic cell

Mature dendritic cell


T cells

T cells

Activation of T and B cells requirees stimulation via:

- Antigen receptor (Signal 1)
- Costimulatory molecules (Signal 2)

B cells




Absence of co-stimulation leads to unresponsiveness

Peripheral tolerance




Effector mechanisms of adaptive immunity

CD8+ T cells (Cytotoxic T cells)



Produce proteins that lyse cells


CD4+ T cells (Helper T cells)



Different subtypes: Th1, Th2, Th17, Tregs



Effector mechanisms of adaptive immunity



B Cells

Ab function:


- Neutralize
- Block protein functions
- Promote engulfement
- Induce complementmediated cell lysis

Different classes (isotypes) of Ab

- IgM
- IgG
- IgE
- IgA



Significance of immunological memory



- Typically expressed by professional APCs
- Presents peptides derived from exogenous proteins



Immune responses can be beneficial or harmful

Antigen	Effect of response to antigen	
	Normal response	Deficient response
Infectious agent	Protective immunity	Recurrent infection
Innocuous substance	Allergy	No response
Grafted organ	Rejection	Acceptance
Self organ	Autoimmunity	Self tolerance
Tumor	Tumor immunity	Cancer




Tumor Immunology

Definitions

- Immunosurveillance: process of immune cells looking for and recognizing pathogens or tumor cells
- Neoantigens: antigens on tumor cells that give the immune system a way to differentiate them from normal cells. Examples: mutant proteins, oncogenic viruses, cancer testis antigens, or differentiation antigens
- Immunoediting: elimination of immunogenic tumor cells leads to a progressively more nonimmunogenic tumor phenotype


The 3 Es of cancer immunoediting









Cancer-Immunity Cycle



Cancer-Immunity Cycle -- regulators



Immunity 2013 39, 1-10DOI: (10.1016/j.immuni.2013.07.012) Copyright © 2013 Elsevier Inc. <u>Terms and Conditions</u> Cancer-Immunity Cycle – therapeutic targets



Thank you